234 related articles for article (PubMed ID: 29936436)
1. Short-term and low-dose IL-2 therapy restores the Th17/Treg balance in the peripheral blood of patients with primary Sjögren's syndrome.
Miao M; Hao Z; Guo Y; Zhang X; Zhang S; Luo J; Zhao X; Zhang C; Liu X; Wu X; Xu D; Zhao J; Lu X; Gao C; Li X
Ann Rheum Dis; 2018 Dec; 77(12):1838-1840. PubMed ID: 29936436
[No Abstract] [Full Text] [Related]
2. Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren's syndrome: a pilot study.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Di Benedetto P; Cipriani P; Giacomelli R; Gerli R
Clin Exp Immunol; 2016 Jun; 184(3):284-92. PubMed ID: 26814615
[TBL] [Abstract][Full Text] [Related]
3. Influence of total glucosides of paeony on PD-1/PD-L1 expression in primary Sjögren's syndrome.
Chen Y; Wang Y; Xu L; Zhu W; Xu C; Xu M; Guo L; Hu W; Xu D; Jing R; Zhu Y; He J; Xu B
Int J Rheum Dis; 2019 Feb; 22(2):200-206. PubMed ID: 30338648
[TBL] [Abstract][Full Text] [Related]
4. Expansion of CD4+CD25-GITR+ regulatory T-cell subset in the peripheral blood of patients with primary Sjögren's syndrome: correlation with disease activity.
Alunno A; Nocentini G; Bistoni O; Petrillo MG; Bartoloni Bocci E; Ronchetti S; Lo Vaglio E; Riccardi C; Gerli R
Reumatismo; 2012 Dec; 64(5):293-8. PubMed ID: 23256104
[TBL] [Abstract][Full Text] [Related]
5. Bufotalin ameliorates experimental Sjögren's syndrome development by inhibiting Th17 generation.
Huang Y; Yang G; Fei J; Wu Y; Yan J
Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1977-1985. PubMed ID: 31950221
[TBL] [Abstract][Full Text] [Related]
6. Blockade of Th17 response by IL-38 in primary Sjögren's syndrome.
Luo D; Chen Y; Zhou N; Li T; Wang H
Mol Immunol; 2020 Nov; 127():107-111. PubMed ID: 32950755
[TBL] [Abstract][Full Text] [Related]
7. IL-17-producing double-negative T cells are expanded in the peripheral blood, infiltrate the salivary gland and are partially resistant to corticosteroid therapy in patients with Sjögren's syndrome.
Alunno A; Bistoni O; Bartoloni Bocci E; Caterbi S; Bigerna B; Pucciarini A; Tabarrini A; Mannucci R; Beghelli D; Falini B; Gerli R
Reumatismo; 2013 Oct; 65(4):192-8. PubMed ID: 24192564
[TBL] [Abstract][Full Text] [Related]
8. Catalpol ameliorates Sjögren's Syndrome by modulating interplay of T and B cells.
Lin R; Hao D; Dong Y; Wang Y
Biomed Pharmacother; 2020 Mar; 123():109806. PubMed ID: 31951976
[TBL] [Abstract][Full Text] [Related]
9. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
[No Abstract] [Full Text] [Related]
10. T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives.
Alunno A; Carubbi F; Bistoni O; Caterbi S; Bartoloni E; Mirabelli G; Cannarile F; Cipriani P; Giacomelli R; Gerli R
Mediators Inflamm; 2015; 2015():243723. PubMed ID: 26060357
[TBL] [Abstract][Full Text] [Related]
11. [Sjögren's disease].
Bijl M; Panders AK; Vissink A; Nikkels PG; Kallenberg CG
Ned Tijdschr Geneeskd; 1994 May; 138(21):1049-52. PubMed ID: 8202174
[No Abstract] [Full Text] [Related]
12. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
13. Th17/Treg cell level and clinical characteristics of peripheral blood of patients with Sjogren's syndrome complicated with primary biliary cirrhosis.
Hao LR; Li XF; Gao C; Cao L; Han ZY; Gao H
Medicine (Baltimore); 2019 Jun; 98(24):e15952. PubMed ID: 31192933
[TBL] [Abstract][Full Text] [Related]
14. Limited efficacy of targeted treatments in Sjögren's syndrome: why?
Tzioufas AG; Goules AV
Clin Exp Rheumatol; 2018; 36 Suppl 112(3):27-28. PubMed ID: 29998826
[No Abstract] [Full Text] [Related]
15. Lycium barbarum Polysaccharide Ameliorates Sjögren's Syndrome in a Murine Model.
Wang Y; Xiao J; Duan Y; Miao M; Huang B; Chen J; Cheng G; Zhou X; Jin Y; He J; Li Z; So KF
Mol Nutr Food Res; 2021 Jun; 65(11):e2001118. PubMed ID: 33825332
[TBL] [Abstract][Full Text] [Related]
16. The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.
Sthoeger Z; Sharabi A; Asher I; Zinger H; Segal R; Shearer G; Elkayam O; Mozes E
Clin Immunol; 2018 Jul; 192():85-91. PubMed ID: 29730433
[TBL] [Abstract][Full Text] [Related]
17. cDNA microarray analysis identifies NR4A2 as a novel molecule involved in the pathogenesis of Sjögren's syndrome.
Takahashi H; Tsuboi H; Asashima H; Hirota T; Kondo Y; Moriyama M; Matsumoto I; Nakamura S; Sumida T
Clin Exp Immunol; 2017 Oct; 190(1):96-109. PubMed ID: 28621822
[TBL] [Abstract][Full Text] [Related]
18. Acquired factor VIII inhibitor in Sjögren's syndrome.
Vintimilla M; Joseph A; Ranganathan P
Arthritis Care Res (Hoboken); 2010 Jul; 62(7):1047-50. PubMed ID: 20589701
[No Abstract] [Full Text] [Related]
19. Effect of Chinese herbal medicine for nourishing yin, supplementing qi, and activating blood on the Th1/Th2 immune balance in peripheral blood in patients with primary Sjogren's syndrome.
Wu GL; Li TY; Fan YS; Yu GY; Chen J
Chin J Integr Med; 2013 Sep; 19(9):696-700. PubMed ID: 23975134
[TBL] [Abstract][Full Text] [Related]
20. Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome.
Ciccia F; Guggino G; Rizzo A; Alessandro R; Carubbi F; Giardina A; Cipriani P; Ferrante A; Cannizzaro A; Giacomelli R; Triolo G
Rheumatology (Oxford); 2014 Jul; 53(7):1313-20. PubMed ID: 24602921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
